TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30201016

Group type: EXPERIMENTAL
Intervention: Lightning strike incidents during recreational activities (hiking, hunting, timberwork)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lightning strikes occurring between June and August
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lightning strikes occurring between 12:00 and 22:00 hours
Number of subjects: 64
Study: 30201601

Group type: EXPERIMENTAL
Intervention: mSMART intervention (smartphone-based contingency management)
Number of subjects: 10
Study: 30201761

Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122) at doses ranging from 0.5-3.5 mg, 28-day continuous dosing cycles
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122)
Number of subjects: 34
Study: 30201821

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 850
Study: 30201849

Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive therapy (rituximab, high-dose pulsed steroids, cyclophosphamide until remission, followed by maintenance therapy with azathioprine)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive therapy
Number of subjects: 22
Study: 30201848

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLCs)
Number of subjects: 25
Study: 30202211

Group type: EXPERIMENTAL
Intervention: Valsartan (V)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (C)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined Valsartan and Chlorthalidone (V + C)
Number of subjects: 72
Study: 30202425

Group type: EXPERIMENTAL
Intervention: Support services on breastfeeding during hospital stay
Number of subjects: 329

Group type: COMPARATOR
Intervention: Higher State-Trait Anxiety Inventory score
Number of subjects: 329

Group type: COMPARATOR
Intervention: Higher intrapartum blood loss
Number of subjects: 329

Group type: COMPARATOR
Intervention: Occurrence of fetal anomalies
Number of subjects: 329

Group type: COMPARATOR
Intervention: Ethnicity (Indians, Malays, other ethnicities)
Number of subjects: 329
Study: 30202530

Group type: EXPERIMENTAL
Intervention: 4-Hz high-frequency oscillation (HFO)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 7-Hz high-frequency oscillation (HFO)
Number of subjects: 17

Group type: COMPARATOR
Intervention: lung protective conventional ventilation (CV)
Number of subjects: 17
Study: 30203081

Group type: EXPERIMENTAL
Intervention: 1 dose of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate
Number of subjects: 50
Study: 30203445

Group type: EXPERIMENTAL
Intervention: Neratinib + regorafenib + sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regorafenib + sildenafil
Number of subjects: 0
Study: 30203580

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study: 30204024

Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound (HIFU)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB) after 12 months
Number of subjects: 27
Study: 30204247

Group type: EXPERIMENTAL
Intervention: larotrectinib
Number of subjects: 5
Study: 30204542

Group type: EXPERIMENTAL
Intervention: Maternal milk lutein concentrations (sample 1: 6.5 μg/dL, sample 2: 7.7 μg/dL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Maternal milk zeaxanthin concentrations (sample 1: 1.6 μg/dL, sample 2: 1.7 μg/dL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Infant plasma lutein and zeaxanthin concentrations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Correlation of infant plasma lutein and zeaxanthin concentrations with milk sample 1
Number of subjects: 56
Study: 30204885

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) with 20 mg Fe
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) with 60 mg Fe + 400 µg folic acid
Number of subjects: 4011
Study: 30205016

Group type: EXPERIMENTAL
Intervention: Medicaid group
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: PCGs of children enrolled in Medicaid
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Baseline responses based on Medicaid status and race/ethnicity
Number of subjects: 1323
Study: 30205124

Group type: EXPERIMENTAL
Intervention: Metastasis-directed stereotactic body radiation therapy (mdSBRT)
Number of subjects: 37
Study: 30205231

Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy followed by reduced-intensity conditioning (RIC) regimen
Number of subjects: 21
Study: 30205314

Group type: EXPERIMENTAL
Intervention: Fibered platinum coil placement
Number of subjects: 56
Study: 30205886

Group type: EXPERIMENTAL
Intervention: IV sodium nitrite 25 mg (low dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IV sodium nitrite 60 mg (high dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: IV sodium nitrite (both doses)
Number of subjects: 120
Study: 30205939

Group type: EXPERIMENTAL
Intervention: MHI-13 (Mental Health Index-13)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: MHI-17 (Mental Health Index-17)
Number of subjects: 686
Study: 30206821

Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 939
Study: 30207748

Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI), n=26
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI) compliant group (n=15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Technosphere insulin (TI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Insulin aspart, n=34
Number of subjects: 60
Study: 30208209

Group type: EXPERIMENTAL
Intervention: Continued appropriate medical therapy (CAMT)
Number of subjects: 120
Study: 30208208

Group type: EXPERIMENTAL
Intervention: Long-term symptom subgroup (symptom duration > 60 months)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Short-term symptom subgroup (symptom duration < 12 months)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Middle-term symptom subgroup (symptom duration 12-60 months)
Number of subjects: 113
Study: 30208871

Group type: EXPERIMENTAL
Intervention: LiverMultiScan™ multiparametric MRI
Number of subjects: 200
Study: 30208971

Group type: EXPERIMENTAL
Intervention: Action-based cognitive remediation (ABCR) for 10 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 58
Study: 30209124

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 717
Study: 30209238

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Higher total cholesterol
Number of subjects: 149
Study: 30209556

Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin, and dexamethasone (GDP) combined with methotrexate (MTX) and pegaspargase (PEG-L)
Number of subjects: 65
Study: 30209610

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided transmural gallbladder drainage (EGBD) using lumen-apposing metal stents (LAMS)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Endoscopic transpapillary drainage (TP)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Percutaneous cholecystostomy tube (PTGBD)
Number of subjects: 372
Study: 30210431

Group type: EXPERIMENTAL
Intervention: Anesthetic management during mechanical thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anesthetic management
Number of subjects: 0
Study: 30210802

Group type: EXPERIMENTAL
Intervention: Web-based eHealth portal (McKesson, Canada, RelayHealth®)
Number of subjects: 41
Study: 30211141

Group type: EXPERIMENTAL
Intervention: Web-Based Motor Intervention
Number of subjects: 0
Study: 30211847

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) for 12 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) + Ribavirin (RBV) for 12 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Daclatasvir (DCV) + Ribavirin (RBV) for 24 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ledipasvir (LDV) + Ribavirin (RBV) for 12 weeks
Number of subjects: 88
Study: 30212302

Group type: EXPERIMENTAL
Intervention: 12-wk supervised, progressive combined exercise training program (aerobic and resistance exercise)
Number of subjects: 21
Study: 30212404

Group type: EXPERIMENTAL
Intervention: 100% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 67% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 33% daily dosing of TDF/FTC for 12 weeks
Number of subjects: 47
Study: 30212436

Group type: EXPERIMENTAL
Intervention: Inguinal lymph node biopsy at baseline and/or after antiretroviral therapy (median 48 weeks after therapy)
Number of subjects: 67
Study: 30212462

Group type: EXPERIMENTAL
Intervention: Thyromental height test
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Cormack-Lehane scale
Number of subjects: 237
Study: 30212850

Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACEs) severity in UCPPS
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Worse physical well-being
Number of subjects: 421

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 421
Study: 30213276

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) course for 8 weeks
Number of subjects: 12
Study: 30213322

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX Score (RSS) after PCI
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Functionally complete revascularization by FFR guidance
Number of subjects: 547
Study: 30213473

Group type: EXPERIMENTAL
Intervention: Portable HEPA filter air cleaner use (1-2 air cleaners in homes from early pregnancy until childbirth)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (no air cleaners)
Number of subjects: 540
Study: 30213581

Group type: EXPERIMENTAL
Intervention: COL3A1 plasma concentration in group 3 (B1 phenotype who developed strictures)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: COMP plasma concentration
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Combination of baseline concentrations of COL3A1 and anti-CSF2
Number of subjects: 161

Group type: COMPARATOR
Intervention: COL3A1 plasma concentration
Number of subjects: 161
Study: 30213611

Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: National Asthma Education and Prevention Program (NAEPP) criteria
Number of subjects: 373
Study: 30213921

Group type: EXPERIMENTAL
Intervention: Aeonose (electronic nose)
Number of subjects: 55
Study: 30214036

Group type: EXPERIMENTAL
Intervention: Nocturia (voiding ≥3 times per night)
Number of subjects: 7343

Group type: EXPERIMENTAL
Intervention: Inclusion of disturbed sleep in the model
Number of subjects: 7343
Study: 30214322

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants (TTI)
Number of subjects: 103
Study: 30214408

Group type: EXPERIMENTAL
Intervention: Adjunctive everolimus (Low exposure: 3-7 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive everolimus (High exposure: 9-15 ng/mL)
Number of subjects: 0
Study: 30214815

Group type: EXPERIMENTAL
Intervention: Camden Weight Loss intervention
Number of subjects: 191
Study: 30215279

Group type: EXPERIMENTAL
Intervention: Phone-based intervention for parents, focusing on time spent discussing weight-related behaviors and behavior change techniques used in sessions.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phone-based intervention for parents, focusing on behavior change techniques used in sessions.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phone-based intervention for parents, focusing on intervention-recommended activities implemented by parents between sessions.
Number of subjects: 100
Study: 30215286

Group type: EXPERIMENTAL
Intervention: Brain temperature monitoring
Number of subjects: 51
Study: 30215671

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT scans at baseline and 4-8 weeks after ART initiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: FDG-PET/CT scans after ART initiation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glut-1 expression of CD4+ cells and monocytes after ART initiation
Number of subjects: 30
Study: 30215677

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg Q4W
Number of subjects: 3817

Group type: COMPARATOR
Intervention: Nivolumab 3 mg/kg Q2W
Number of subjects: 3817

Group type: COMPARATOR
Intervention: Nivolumab 240 mg Q2W
Number of subjects: 3817
Study: 30216219

Group type: EXPERIMENTAL
Intervention: CTC-positive (≥1 CTC/7.5 mL) in high-risk patients
Number of subjects: 242

Group type: COMPARATOR
Intervention: CTC-negative in high-risk patients
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CTC-positive in advanced disease
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CTC-positivity (univariate analysis)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: CTC-status (multivariable analysis)
Number of subjects: 242
Study: 30216360

Group type: EXPERIMENTAL
Intervention: Dys-HDL (HDL inflammatory index, HII)
Number of subjects: 88
Study: 30217150

Group type: EXPERIMENTAL
Intervention: Transcranial focused ultrasound (tFUS) to the thumb representation in M1
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham neuromodulation
Number of subjects: 5
Study: 30217223

Group type: EXPERIMENTAL
Intervention: Transcatheter delivery of autologous bone marrow-derived advanced therapy medicinal product CD133
Number of subjects: 0
Study: 30217227

Group type: EXPERIMENTAL
Intervention: TSFE using osteotomes with bone grafting
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TSFE using osteotomes without bone grafting
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: modified TSFE with bone grafting
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: modified TSFE without bone grafting
Number of subjects: 120
Study: 30217228

Group type: EXPERIMENTAL
Intervention: Salvianolate injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 30217377

Group type: EXPERIMENTAL
Intervention: Smartphone-enabled home-based cardiac rehabilitation program
Number of subjects: 18
Study: 30217421

Group type: EXPERIMENTAL
Intervention: 2016 ESC Guidelines Class I indication (538 patients)
Number of subjects: 930

Group type: COMPARATOR
Intervention: 2013 ESC Guidelines Class I indication (650 patients)
Number of subjects: 930
Study: 30217536

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (2 ng/kg body weight)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prediction error signal (discrepancy between immune signal and sickness expectancy)
Number of subjects: 22
Study: 30217579

Group type: EXPERIMENTAL
Intervention: Established obstructive sleep apnea screening tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home sleep apnea testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age, body mass index, neck circumference, frequently witnessed apneas, and highly likely to fall asleep while driving
Number of subjects: 0
Study: 30217671

Group type: EXPERIMENTAL
Intervention: Trabectedin and olaparib combination treatment
Number of subjects: 50
Study: 30218434

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 517

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 517
Study: 30218651

Group type: EXPERIMENTAL
Intervention: Optogenetic approaches to vision restoration
Number of subjects: 0
Study: 30218977

Group type: EXPERIMENTAL
Intervention: LY3039478 50mg/75mg three times per week for 28-day cycle until disease progression
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: LY3039478
Number of subjects: 69
Study: 30219086

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Acupuncture (AC)
Number of subjects: 290
Study: 30219274

Group type: EXPERIMENTAL
Intervention: Immunocryosurgery (5% imiquimod cream daily for five weeks and cryosurgery on day fourteen)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Repeat immunocryosurgery cycles
Number of subjects: 55
Study: 30219367

Group type: EXPERIMENTAL
Intervention: Tdap vaccine in pregnant women
Number of subjects: 599

Group type: COMPARATOR
Intervention: Tdap vaccine in nonpregnant women
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Tdap vaccine in pregnant women and nonpregnant women
Number of subjects: 599
Study: 30219500

Group type: EXPERIMENTAL
Intervention: Smart Somatotopic Quantitative Sensation Testing (S ST QSTing) using Computer Assisted Sensation Evaluator IVc (CASE IVc)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Smart Somatotopic Quantitative Sensation Testing (S ST QSTing)
Number of subjects: 169
Study: 30219628

Group type: EXPERIMENTAL
Intervention: encorafenib plus binimetinib
Number of subjects: 577

Group type: COMPARATOR
Intervention: vemurafenib
Number of subjects: 577

Group type: COMPARATOR
Intervention: encorafenib
Number of subjects: 577
Study: 30219763

Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Microcalorimetry
Number of subjects: 57

Group type: COMPARATOR
Intervention: SF Culture
Number of subjects: 57
Study: 30219791

Group type: EXPERIMENTAL
Intervention: Venous sinus stenting (VSS)
Number of subjects: 70
Study: 30219793

Group type: EXPERIMENTAL
Intervention: Intervention group (n=306) booked for IUD insertion 1-4 weeks after MTOP at the hospital.
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (n=299) advised to contact their primary healthcare (PHC) centre for follow-up and IUD insertion.
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control group (n=299) for IUD insertion within 3 months.
Number of subjects: 605
Study: 30219858

Group type: EXPERIMENTAL
Intervention: l-carnitine treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: no l-carnitine treatment
Number of subjects: 18
Study: 30219915

Group type: EXPERIMENTAL
Intervention: Atezolizumab i.v. every 3 weeks for 16 cycles, up to 1 year or until loss of clinical benefit.
Number of subjects: 32
Study: 30219920

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 22311
Study: 30219937

Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of quality of life (QOL) using the Medical Outcome Study-HIV Survey (MOS-HIV)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Surrogates' assessment of patients' quality of life (QOL) using the Palliative care Outcome Scale (POS)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Shared HIV diagnosis between patient and surrogate
Number of subjects: 223
Study: 30220300

Group type: EXPERIMENTAL
Intervention: Multiband mucosectomy (MBM) device
Number of subjects: 291
Study: 30220708

Group type: EXPERIMENTAL
Intervention: Everolimus and pazopanib (E/P)
Number of subjects: 19
Study: 30221011

Group type: EXPERIMENTAL
Intervention: Doxorubicin and sildenafil (100 mg by mouth daily during therapy, three times daily on the day of doxorubicin)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard doxorubicin chemotherapy alone
Number of subjects: 27
Study: 30221150

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg EOW
Number of subjects: 28
Study: 30221344

Group type: EXPERIMENTAL
Intervention: Minor injuries
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Moderate injuries
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Severe injuries
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 1191
Study: 30221827

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000-500 mg every 8 hours, adjusted for CrCL ≤ 50 mL/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study: 30222141

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 63

Group type: COMPARATOR
Intervention: COC
Number of subjects: 63
Study: 30222972

Group type: EXPERIMENTAL
Intervention: EUS-guided photodynamic therapy (PDT) with intravenous porfimer sodium followed by EUS-PDT
Number of subjects: 12
Study: 30223771

Group type: EXPERIMENTAL
Intervention: DelApp smartphone application for assessing inattention in delirium, administered within 3 hours of reference standard assessment.
Number of subjects: 500
Study: 30223779

Group type: EXPERIMENTAL
Intervention: Remote health coach intervention
Number of subjects: 30
Study: 30223802

Group type: EXPERIMENTAL
Intervention: MRI-based exclusion of the non-tumor-bearing parts of the uterus from the target volume
Number of subjects: 0
Study: 30223870

Group type: EXPERIMENTAL
Intervention: Family centered Function-focused Care
Number of subjects: 438

Group type: COMPARATOR
Intervention: Education-only (Control)
Number of subjects: 438
Study: 30223874

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) with demonstrations, kit distribution, and private spaces for use
Number of subjects: 15

Group type: COMPARATOR
Intervention: Optimized standard of care (optimized PITC with additional training, job aids, and monitoring)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard of care (routine provider-initiated testing and counseling)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 15
Study: 30223877

Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 192
Study: 30224031

Group type: EXPERIMENTAL
Intervention: CHADS score
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Nine scores
Number of subjects: 1490
Study: 30224193

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (15 mg single oral dose)
Number of subjects: 16
Study: 30224284

Group type: EXPERIMENTAL
Intervention: Metformin, pioglitazone, and lifestyle therapy
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Metformin, pioglitazone, GLP-1 receptor agonist, and lifestyle therapy
Number of subjects: 422

Group type: COMPARATOR
Intervention: Lifestyle therapy only
Number of subjects: 422
Study: 30224303

Group type: EXPERIMENTAL
Intervention: iNEWS score (infant early nutrition warning score)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High iNEWS score
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dietetic assessment
Number of subjects: 42
Study: 30224322

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents
Number of subjects: 22803

Group type: COMPARATOR
Intervention: No neuromuscular blocking agents
Number of subjects: 22803
Study: 30224333

Group type: EXPERIMENTAL
Intervention: Limbr mobile phone app suite including daily visual self-reports, rehabilitation video tutorials, passive activity-level measurement, and chat-based health coaching.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Your Activities of Daily Living module
Number of subjects: 93